b-glass™

b-glass™ (45S5 composition) is a unique biomaterial that readily facilitates both soft and hard tissue attachment. 45S5 glass has been long established as a safe bioactive implantable biomaterial with regulatory track record for clinical use.

The bioactive hydrated silica layer that forms at the bio-interface supports cell-matrix and cell adhesion facilitating tissue ingrowth and conduction in vivo.

b-glass™ can also be used to induce radio-opacity as a temporary imaging tag, and be included in coatings or as a filler for gels, polymers, polymer textiles and scaffolds. It can also be bonded onto metallic and ceramic implant surfaces as a glass film or enamel.

b-glass™  can be used to promote tissue attachment, osteogenesis, angiogenesis, antibacterial activity, radioopacity, elution profiles and temporary mechanical modulation of bioresorbable scaffolds or materials.

variotis™

variotis™ is a versatile thick 3D scaffold for in vitro and in vivo research applications. It can be used as is with good cell attachment or with b-glass™ for enhanced response.

The elastomeric soft-tissue like scaffold has >95% interconnected porosity that mimics tissue mechanical properties. The scaffold is capable of extending up to 300% extension before failure in its native form. The porosity of the scaffold can be adjusted by compression setting the scaffold at the softening temperature. By tuning the porosity of variotis™ the scaffold Youngs modulus can range from 40kPa (skin/adipose) to 400MPa (cartilage).

variotis™ has been successfully used for a wide range of cell culture and tissue engineering applications including for skin, chronic wounds, adipose, bone, stem cells, neural cells, various cancer models and bacterial cell cultures.

variotis™ can be thermally bonded with powder-coatings, plasma treated to facilitate physical bonding of bioactive or therpeutic compounds on the molecular level. It can also be evaporatively coated (PLD) or sputter coated with bioactive coatings including bioresorbable metallic coatings.

iaxsys™

The iaxsys™ is a unique in vitro mechanobiology actuator that is compatible with established cell culture methods, consumables and incubators.

This versatile bioreactor platform facilitates near-physiologic strain of 2D membranes and scaffolds, thick 3D scaffolds (variotis™), ex vivo tissues, and soft tissue implants (eg bovine pericardium xenograft heart valve materials) within standard cell culture plates and flasks.

Quasi-static strain or cyclic strain can be applied uniformly to 6 samples simultaneously within a 6 well cell plate with a specified rate and number of cycles. Depending on the configuration, tensile or compression stresses are imparted.

When the iaxsys™ is used to actuate variotis™ scaffolds for mechanobiology studies in standard 6 well cell culture plates, the quality of RNA sampled is of a very high level. Unlike biologically derived gels and scaffolds, the fully synthetic variotis™ with b-glass™ avoids any contamination. The use of standard cell well plates that are single-use further mitigates any contamination risk while allowing studies to accrue sufficient replicates at moderate cost.

Accessory components can be utilized with the iaxsys™ to impart biaxial strain, fluid sheer, hydrostatic pressure and shock.

Bioactive Glass Developments*

1969 Invention of the 45S5 glass composition (45S5 Bioglass®)
1977 Treatment of ear diseases by using Ceravital® glass-ceramics
1978 Ocular implant (biocompatibility with corneal tissue)
1985 Approval by Food and Drug Administration (FDA) of 45S5 Bioglass® implant MEP®
1987 Treatment of liver cancer (radioactive glasses)
1988 Clinical use of the 45S5 Bioglass®-based Endosseous Ridge Maintenance Implant
1993 FDA approval of PerioGlas (45S5 Bioglass® particulate used for bone/dental repair)
1998 Peripheral nerve repair
1999 FDA approval of radioactive glasses (TheraSphere®) for cancer treatment
2000 Wound healing
2002 FDA approval of Medpor®-PlusTM (polyethylene/45S5 Bioglass® composite).
2003 Antibacterial (Zn-containing) bone/dental cements
2004 Lung tissue engineering
2004 Use of mesoporous bioactive glass (MBG) as a drug delivery system
2005 Skeletal muscle and ligament repair
2005 Treatment of gastrointestinal ulcers
2010 Cardiac tissue engineering
2011 Commercialization of a cotton-candy borate bioactive glass for wound healing
2012 Embolization of uterine fibroids
2012 Spinal cord repair
2018 Use of radioactive glasses (TheraSphere®) in cancer patients

* F Baino et al, Bioactive Glasses: Where Are We and Where Are We Going?, J Funct Biomater, 9(25) 2018

cell growth on and between glass granules

Innovation Opportunities

b-glass™  is available as powder or granule form in 10g or 100g amounts. Specialized formulations, forms or amounts can be arranged with sufficient lead time.

variotis™ can be further modified and augmented with hydrogels, proteins, incorporated semipermeable membranes, or formed into anatomical geometries from a CT or MRI scan.

iaxsys™ is a versatile in vitro platform that is currently undergoing further development to incorporate electrical and photobiomodulation modules.

Biometic supports collaboration and innovation partnerships.